Global Healthcare Study on Hidradenitis Suppurativa
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa). Basic parameters: from 14 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Switzerland
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The Global Healthcare Study on Hidradenitis Suppurativa (GHSHS) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.
Detailed description
The study employs a combined retrospective and prospective design, collecting data from routine clinical care and medical records spanning from January 2020 through the study conclusion.
Primary outcome measures
- International Hidradenitis Suppurativa Severity Score System (IHS4) [Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.]
Secondary outcome measures (6)
- Hurley Staging System [Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.]
- Sartorius Hidradenitis Suppurativa Severity Score (HSS) [Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.]
- Physician Global Assessment (PGA) [Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.]
- Dermatology Life Quality Index (DLQI) [Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.]
- Patient-reported Numerical Rating Scale (NRS) for severity of hidradenitis suppurativa [Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.]
- Patient-reported Numerical Rating Scale (NRS) for pain related to hidradenitis suppurativa [Time frame: Baseline and follow-up visits every 6-12 months for up to 5 years.]
Eligibility criteria
Inclusion criteria
- Signed General Consent Form, or equivalent document
- Confirmed diagnosis of Hidradenitis Suppurativa
Exclusion criteria
- Inability to provide informed consent.
- Datasets with ambiguous or unclear diagnosis.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Switzerland · 1 center
- University of Zurich — Zurich
Identifiers
NCT: NCT07659769 · 2024-01704-3